Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $36,300.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the business’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $7.26, for a total value of $36,300.00. Following the completion of the transaction, the insider owned 195,993 shares of the company’s stock, valued at $1,422,909.18. This represents a 2.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, October 5th, Philippe Menu sold 7,394 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.13, for a total value of $60,113.22.
• On Tuesday, August 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.68, for a total value of $43,400.00.
• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total value of $28,300.00.

SOPHiA GENETICS Stock Performance

NASDAQ:SOPH traded down $0.56 during mid-day trading on Friday, reaching $6.73. The company’s stock had a trading volume of 915,442 shares, compared to its average volume of 625,793. SOPHiA GENETICS SA has a 12-month low of $3.75 and a 12-month high of $8.98. The firm’s fifty day moving average price is $7.96 and its two-hundred day moving average price is $6.24. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The stock has a market cap of $564.58 million, a P/E ratio of -5.85 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, equities analysts forecast that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Silverberg Bernstein Capital Management LLC boosted its position in SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after purchasing an additional 4,155 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS during the 1st quarter valued at about $50,000. 1492 Capital Management LLC lifted its stake in shares of SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after purchasing an additional 17,406 shares during the period. Finally, Royal Bank of Canada lifted its stake in shares of SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the period. Institutional investors own 31.59% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on SOPH shares. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, October 12th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research lifted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.